{"disease":{"id":"endocrine-breast-diseases","name":"endocrine breast diseases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07581834","title":"Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT03939156","title":"Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03373708","title":"Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Zhiyong Yu","has_results":false},{"nct_id":"NCT02909452","title":"Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02897778","title":"Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}